MeiraGTx Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 143.10K shares, a 2315.17% increase year-over-year.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 8.21K shares, a 1187.62% increase year-over-year.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 29.82K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 1.90K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 38.28K shares.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 3.86K shares, a 85.73% decline from fiscal 2022.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 27.08K shares, a 85.49% decline from fiscal 2021.
- MeiraGTx Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 186.64K shares, a 70.76% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 143.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 183.03K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 8.21K shares 10-Q · filed 2026-05-14 | 45.86K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 29.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 38.28K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 1.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | 5.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | |
| 2025-03-31 | 638.00 shares 10-Q · filed 2025-05-13 | |
| 2023-12-31 | 3.86K shares 10-K · filed 2024-03-15 | |
| 2022-12-31 | 9.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 27.08K shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 152.47K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 159.40K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-03-31 | 18.07K shares 10-Q · filed 2022-05-12 | 186.78K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-12-31 | 134.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 186.64K shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 6.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 79.22K shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | 27.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 128.59K shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | 17.92K shares 10-Q · filed 2021-05-11 | 101.21K shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | 26.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 109.30K shares 10-K · filed 2022-03-10 |
| 2020-09-30 | 56.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 207.49K shares derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 160.32K shares derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | 26.01K shares 10-Q · filed 2020-05-07 | 160.54K shares derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | 125.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 134.53K shares 10-K · filed 2021-03-11 |
| 2019-09-30 | 9.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | |
| 2019-06-30 | 225.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-14 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | |
| 2017-12-31 | 1.29K shares 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |